These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 24064818)

  • 1. [Genomic abnormalities and pathophysiology in myelodysplastic syndrome].
    Chiba S
    Rinsho Ketsueki; 2013 Oct; 54(10):1687-96. PubMed ID: 24064818
    [No Abstract]   [Full Text] [Related]  

  • 2. [Basic science and pathophysiology of MDS: from a view of its neoplastic aspect and the molecular basis].
    Ichikawa M; Kurokawa M
    Rinsho Ketsueki; 2013 Jan; 54(1):5-13. PubMed ID: 23391642
    [No Abstract]   [Full Text] [Related]  

  • 3. [New insight into myelodysplastic syndromes and related myeloid disorders].
    Ogawa S
    Rinsho Ketsueki; 2013 Jun; 54(6):533-7. PubMed ID: 23823091
    [No Abstract]   [Full Text] [Related]  

  • 4. Genome-wide analysis of copy number changes and loss of heterozygosity in myelodysplastic syndrome with del(5q) using high-density single nucleotide polymorphism arrays.
    Wang L; Fidler C; Nadig N; Giagounidis A; Della Porta MG; Malcovati L; Killick S; Gattermann N; Aul C; Boultwood J; Wainscoat JS
    Haematologica; 2008 Jul; 93(7):994-1000. PubMed ID: 18508791
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessing clonal haematopoiesis: clinical burdens and benefits of diagnosing myelodysplastic syndrome precursor states.
    Gondek LP; DeZern AE
    Lancet Haematol; 2020 Jan; 7(1):e73-e81. PubMed ID: 31810765
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathophysiology and treatment of the myelodysplastic syndrome with isolated 5q deletion.
    Jädersten M
    Haematologica; 2010 Mar; 95(3):348-51. PubMed ID: 20207839
    [No Abstract]   [Full Text] [Related]  

  • 7. Are the current guidelines for identification of myelodysplastic syndrome with germline predisposition strong enough?
    Calvete O; Mestre J; Durmaz A; Gurnari C; Maciejewski JP; Solé F
    Br J Haematol; 2023 Apr; 201(1):e5-e11. PubMed ID: 36717968
    [No Abstract]   [Full Text] [Related]  

  • 8. Myelodysplastic syndromes.
    Tefferi A; Vardiman JW
    N Engl J Med; 2009 Nov; 361(19):1872-85. PubMed ID: 19890130
    [No Abstract]   [Full Text] [Related]  

  • 9. Unusual course of myelodysplastic syndrome with presumed familial origin.
    Bacher U; Ocheni S; Schafhausen P; Oyekunle A; Dierlamm J; Zander AR; Bokemeyer C; Haferlach T; Kröger N
    Acta Haematol; 2011; 126(4):234-7. PubMed ID: 21952642
    [No Abstract]   [Full Text] [Related]  

  • 10. Germ line tissues for optimal detection of somatic variants in myelodysplastic syndromes.
    Padron E; Ball MC; Teer JK; Painter JS; Yoder SJ; Zhang C; Zhang L; Moscinski LC; Rollison DE; Gore SD; Bejar R; Walter MJ; Sekeres MA; Komrokji RS; Epling-Burnette PK
    Blood; 2018 May; 131(21):2402-2405. PubMed ID: 29661788
    [No Abstract]   [Full Text] [Related]  

  • 11. Acquired mutation the key to MPDs.
    Everington T
    Practitioner; 2007 Jan; 251(1690):30, 32, 35. PubMed ID: 17290854
    [No Abstract]   [Full Text] [Related]  

  • 12. The biology and treatment of myelodysplastic syndromes.
    Raza A; Galili N
    Rinsho Ketsueki; 2013 Oct; 54(10):1730-6. PubMed ID: 24064823
    [No Abstract]   [Full Text] [Related]  

  • 13. First Korean case of Emberger syndrome (primary lymphedema with myelodysplasia) with a novel GATA2 gene mutation.
    Seo SK; Kim KY; Han SA; Yoon JS; Shin SY; Sohn SK; Moon JH
    Korean J Intern Med; 2016 Jan; 31(1):188-90. PubMed ID: 26767875
    [No Abstract]   [Full Text] [Related]  

  • 14. Detection of isocitrate dehydrogenase 1 mutation R132H in myelodysplastic syndrome by mutation-specific antibody and direct sequencing.
    Andrulis M; Capper D; Luft T; Hartmann C; Zentgraf H; von Deimling A
    Leuk Res; 2010 Aug; 34(8):1091-3. PubMed ID: 20227112
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Abnormalities of the expression of cytokines and their receptors in myelodysplastic syndromes].
    Fontenay-Roupie M; Dreyfus F
    Pathol Biol (Paris); 1997 Sep; 45(7):569-72. PubMed ID: 9404481
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic molecular markers in myelodysplastic syndromes.
    Neukirchen J; Haas R; Germing U
    Expert Rev Hematol; 2009 Oct; 2(5):563-75. PubMed ID: 21083021
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular genetic aspects of myelodysplastic syndromes.
    Bartram CR
    Semin Hematol; 1996 Apr; 33(2):139-49. PubMed ID: 8722684
    [No Abstract]   [Full Text] [Related]  

  • 18. New clues to the molecular pathogenesis of myelodysplastic syndromes.
    Jädersten M; Hellström-Lindberg E
    Exp Cell Res; 2010 May; 316(8):1390-6. PubMed ID: 20211165
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oncogene mutation and prognosis in the myelodysplastic syndromes.
    Padua RA; West RR
    Br J Haematol; 2000 Dec; 111(3):873-4. PubMed ID: 11122149
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Myelodysplastic syndromes.
    Cachia PG; Padua RA
    Scott Med J; 1994 Feb; 39(1):5-7. PubMed ID: 8720748
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.